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Abstract
Background: Depression and obesity are widespread and 
closely linked. Brain-derived neurotrophic factor (BDNF) and 
vitamin D are both assumed to be associated with depres-
sion and obesity. Little is known about the interplay between 
vitamin D and BDNF. We explored the putative associations 
and interactions between serum BDNF and vitamin D levels 
with depressive symptoms and abdominal obesity in a large 
population-based cohort. Methods: Data were obtained 
from the population-based Study of Health in Pomerania 
(SHIP)-Trend (n = 3,926). The associations of serum BDNF and 
vitamin D levels with depressive symptoms (measured using 
the Patient Health Questionnaire) were assessed with binary 
and multinomial logistic regression models. The associa-
tions of serum BDNF and vitamin D levels with obesity (mea-
sured by the waist-to-hip ratio [WHR]) were assessed with 
binary logistic and linear regression models with restricted 
cubic splines. Results: Logistic regression models revealed 
inverse associations of vitamin D with depression (OR = 
0.966; 95% CI 0.951–0.981) and obesity (OR = 0.976; 95% CI 
0.967–0.985). No linear association of serum BDNF with de-
pression or obesity was found. However, linear regression 
models revealed a U-shaped association of BDNF with WHR 
(p < 0.001). Conclusion: Vitamin D was inversely associated 
with depression and obesity. BDNF was associated with ab-
dominal obesity, but not with depression. At the population 
level, our results support the relevant roles of vitamin D and 
BDNF in mental and physical health-related outcomes.
© 2018 S. Karger AG, Basel
A. Goltz and D. Janowitz contributed equally to this work.
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Introduction
Depression and obesity are 2 widespread medical con-
ditions with major public health implications [1, 2]. Both 
conditions are closely linked; recently, a bidirectional as-
sociation was detected: obesity increases the risk of devel-
oping depression by 55%, whereas depressed patients 
have a 58% increased risk of developing obesity [3]. Little 
is known about the interplay between BDNF and vitamin 
D. In a recently published study, obesity was related to a 
reduced BDNF concentration in the hippocampus and 
vitamin D treatment increased this concentration [4]. 
However, that study was conducted in rats only, and 
therefore results may not apply to humans. 
BDNF is, among others, an important growth factor in 
the central and peripheral nervous system, especially in 
hippocampal and cortical areas [5]. It plays a key role in 
adult neurogenesis as well as in the processes of learning 
and memorizing [5]. Reduced serum BDNF levels have 
been found to be associated with depressive symptoms or 
impaired memory performance. Given that BDNF passes 
the blood-brain barrier and circulating peripheral BDNF 
levels reflect central BDNF levels [6], BDNF has been sug-
gested as a potential biomarker for different mental health 
conditions and particularly mood disorders [7, 8]. BDNF 
is expressed not only in neuronal but also in non-neuro-
nal peripheral tissues [9, 10]. Most of the peripheral 
BDNF is stored in platelets [11, 12]. Recent evidence sug-
gests that low BDNF levels in patients with depressive dis-
orders mainly result from changes in platelet and mega-
karyocyte counts [12, 13]. Moreover, previous studies 
have revealed moderating effects of genetic epistasis be-
tween the BDNF Val66Met polymorphism (rs6265) with 
serotonin transporter 1 functional SNP (rs25531) and 
childhood adversity on depression susceptibility [14, 15]. 
The association between BDNF and obesity is only in-
sufficiently understood. Proinflammatory cytokines like 
tumor necrosis factor are upregulated in adipose tissue of 
obese individuals and promote neuronal death in the 
brain [16, 17]. Results from Nakahashi et al. [9] showed 
that BDNF is involved in neuronal repair processes. Fur-
thermore, BDNF modulates energy homeostasis by inter-
acting with several neuropeptides, including leptin [18]. 
Leptin is mostly expressed in adipose tissue and regulates, 
among others, glucose and lipid metabolism [19]. A study 
from 2006 reported lower serum BDNF levels in 328 
obese children and adolescents after adjusting for platelet 
counts [20]. In contrast, other studies with small sample 
sizes (n < 100) described higher BDNF levels in obese 
women compared to healthy controls [21–23]. Those pre-
vious studies mainly defined obesity based on the body 
mass index (BMI). Unlike the BMI, which does not pro-
vide information on regional body fat distribution [24], 
the waist-to-hip ratio (WHR) is an index for subcutane-
ous as well as intra-abdominal adipose tissue. It is more 
strongly related to cardiovascular diseases and overall 
mortality than BMI [25, 26]. 
Vitamin D deficiency is a considerable global health 
problem [27, 28]. The latitude and season determine the 
amount of vitamin D produced by the skin [29], the major 
source of vitamin D, followed by diet and dietary supple-
ments. Thus, in Europe, for example, but also in North 
America, circulating 25-hydroxy vitamin D levels have a 
large seasonal variation [30] with lower levels of vitamin 
D and higher proportions of vitamin D deficiency ob-
served in winter compared to summer [29]. Several stud-
ies including a meta-analysis of 14 studies have suggested 
that vitamin D deficiency is associated with depressive 
symptoms [31–33]. A cross-sectional study from Finland 
reported that vitamin D was inversely associated with 
depression even after adjusting for lifestyle, sociodemo-
graphic, and metabolic factors [34]. Previous studies have 
also detected an association of low vitamin D levels with 
depressive disorders and assigned a key role to vitamin D 
in various physiological processes [35, 36]. Vitamin D re-
ceptors are widespread throughout the central nervous 
system as well as other tissues and influence early child-
hood brain development and adult brain function [36]. 
Vitamin D initiates the synthesis of serotonin, a hormone 
strongly linked to depression [37]. By activating tran-
scription of the serotonin-synthesizing gene [35] vitamin 
D modifies the production and release of neurotrophic 
factors via membrane-associated and nuclear vitamin D 
receptors in neuronal and non-neuronal cells of the cen-
tral nervous system [36]. In fact, low vitamin D levels pro-
mote depressive disorders [35, 38, 39]. Although previous 
studies have revealed an inverse association between vi-
tamin D and depressive disorders, recent studies report 
inconsistent results. For instance, a retrospective study 
with more than 500 participants found no association be-
tween low vitamin D levels and depression [40]. 
Vitamin D deficiency is also associated with obesity 
[41–43]. For example, inverse associations of vitamin D 
with total body fat and the presence of the metabolic syn-
drome in middle aged and elderly subjects have been de-
scribed [44]. These observations might be related to the 
reduced bioavailability of vitamin D in obesity, caused by 
an increased uptake in adipose tissue [45].
In summary, conflicting results regarding the associa-
tion of BDNF and vitamin D with depression and obesity 
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have been reported. Additionally, previous studies have 
been limited by small sample sizes [5, 21–23] or lacking 
adjustment for confounders like platelets and fibrinogen 
for associations with BDNF [21–23] and like smoking for 
associations with vitamin D [31]. We addressed these 
limitations by investigating a large population-based 
study of men and women: the Study of Health in Pomer-
ania (SHIP)-Trend. Based on data of this cohort we elab-
orated the associations of BDNF and vitamin D with de-
pressive symptoms or obesity. We hypothesized that both 
BDNF and vitamin D are inversely associated with de-
pression and obesity and that BDNF and vitamin D show 
interactions with depression and obesity. The aim of our 
study was to investigate these associations in a large pop-
ulation-based sample to extend previously reported find-
ings and to establish a basis for future research. Further 
knowledge about BDNF and vitamin D in association 
with depression and obesity may allow methods to pre-
vent disease or support therapeutic options, i.e. vitamin 
D supplementation. 
Materials and Methods
SHIP is a population-based project in northeast Germany that 
consists of 2 independent cohorts: SHIP and SHIP-Trend. Its ob-
jective is to determine the prevalence and incidence of risk factors 
and diseases and to investigate associations among risk factors and 
diseases [46, 47]. Both cohorts were selected from the general pop-
ulation in West Pomerania, a region in the northeast of Germany 
(latitude: 54° north). In both cohorts, only individuals with Ger-
man citizenship were included. Moreover, participation in the 
SHIP cohort was an exclusion criterion for participation in the 
SHIP-Trend cohort. 
The present cross-sectional study includes data from the SHIP-
Trend baseline examination [46–48], in which vitamin D and 
BDNF levels were determined. In detail, a stratified random sam-
ple of 10,000 adults (net sample size: n = 8,826) aged 20–79 years 
was drawn from the local population registries. Stratification vari-
ables were age, sex, and city/county of residence. Among the in-
vited individuals, 4,420 men and women chose to participate 
(50.1% response) in the baseline examinations between 2008 and 
2012. Further details on the study design, protocols, and sampling 
methods have been reported elsewhere [46, 47]. All investigations 
were carried out in accordance with the Declaration of Helsinki, 
including written informed consent from all participants. The sur-
vey and study methods were approved by an institutional review 
board (SHIP-Trend [BB 39/09]: Ethics Committee of the Univer-
sity of Greifswald).
Interview and Physical Examination
The SHIP-Trend examinations were performed throughout 
the year. The season of examination was defined as winter (De-
cember to May) or summer (June to November). Trained and cer-
tified interviewers collected information on medical history, so-
ciodemographic, and health-related factors via a computer-assist-
ed interview. Physical activity and smoking status were assessed by 
self-report. Participants were defined as physically inactive if they 
reported less than 1 h of physical activity per week during summer 
and winter. Women were classified as pre- or postmenopausal 
based on age and self-reported menstrual cycling. All women 
younger than 40 years of age as well as women between 40 and 60 
years of age, who reported menstrual cycling, were defined as pre-
menopausal, and all other women were defined as postmenopaus-
al. Data on current depressive symptoms were collected using the 
Patient Health Questionnaire (PHQ-9) [49]. Depression was de-
fined as a PHQ-9 score ≥10 out of 27 achievable points. The PHQ-9 
is a self-report measure of depressive disorders. It consists of 9 
items that are rated according to how much a symptom has both-
ered during the last 2 weeks, each on a scale of 0–3. The items 
match the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) criteria of major depression [50]. We 
used an item total score which summarizes the scores of the single 
items, ranging from 0 to 27. A cut-off point of 10 or above repre-
sents a good diagnostic method of screening for depressive disor-
ders [49]. Moreover, the PHQ-9 can be used to define depression 
severity [50]. For this, PHQ-9 scores are categorized into the fol-
lowing 5 groups: none (< 5), mild (5–9), moderate (10–14), mod-
erately severe (15–19), and severe (≥19) [50]. In our study the 
number of subjects with PHQ-9 scores ≥15 was low (n = 63; 1.6%), 
and therefore we collapsed the 2 upper categories.
All study participants were asked to bring all medications taken 
in the last 7 days prior to the examination. The drugs were classified 
according to the anatomical therapeutic chemical classification sys-
tem (ATC) [51]. Antidepressant drugs were defined as ATC N06A, 
antidiabetic drugs as ATC A10, lipid-lowering drugs as ATC C10, 
and antihypertensive drugs as ATC C02, C03, C07, C08, and C09. 
The physical examination included measurement of anthropomet-
ric parameters with calibrated scales. Waist circumference was mea-
sured midway between the lower rib margin and the iliac crest on 
the horizontal plane. Hip circumference was measured at the great-
est circumference between the highest point of the iliac crest and the 
crotch. Both waist and hip circumferences were measured in centi-
meters. The WHR was calculated from the respective measures 
(waist circumference divided by hip circumference). We defined 
obesity according to the German Society for Sports Medicine and 
Prevention was a WHR > 0.85 in females and > 1.0 in males [52].
Blood Sampling and Laboratory Measurements
In SHIP-Trend single-occasion blood samples were drawn 
from the cubital vein of participants in the supine position follow-
ing standardized procedures. The sampling was performed be-
tween 7: 30 a.m. and 1: 00 p.m. The majority (61.2%) of the study 
participants provided fasting (> 8 h) blood samples, and the re-
maining samples (38.8%) were obtained from nonfasting subjects. 
A maximum of 65.5 mL of blood was collected in 13 tubes, includ-
ing EDTA, citrate, serum, and PAXgene tubes. Directly after sam-
pling, EDTA and serum tubes were cooled down to 4  ° C, while 
citrate tubes were stored at room temperature. Hourly transport to 
the central laboratory (Institute of Clinical Chemistry and Labora-
tory Medicine, University Medicine Greifswald) was arranged. Af-
ter arrival at the laboratory, the samples were immediately pro-
cessed. When necessary, samples were centrifuged at 2,550 g for 15 
min at 8  ° C. The samples were then analyzed or stored at –80  ° C in 
the Integrated Research Biobank (LiCONiC, Lichtenstein). BDNF 
levels were measured in serum with a quantitative sandwich en-
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zyme immunoassay technique (Quantikine Human Free BDNF 
Immunoassay, R&D Systems, Inc., Minneapolis, MN, USA). Two 
concentrations of control material were measured. The coeffi-
cients of variation for BDNF were 14.95% at low levels (129 pg/mL) 
and 5.81% at high levels (667 pg/mL) of control material. Serum 
25-hydroxy vitamin D levels were measured on an IDS-iSYS 
Multi-Discipline Automated Analyzer (Immunodiagnostic Sys-
tems Limited, Frankfurt am Main, Germany). Three concentra-
tions of control material were measured. The coefficients of varia-
tion for vitamin D were 11.6 at low, 9.1 at medium, and 10.6% at 
high levels of control material. The participants’ vitamin D status 
was defined as deficient (vitamin D < 20 ng/mL) or sufficient (vi-
tamin D ≥20 ng/mL) according to the recommendation of the 
German Nutrition Society [53]. Serum creatinine was measured 
with a modified kinetic Jaffé method (Siemens Dimension Vista; 
Siemens Healthcare Diagnostics, Eschborn, Germany). The esti-
mated glomerular filtration rate was estimated according to the 
4-variable Modification of Diet in Renal Disease formula [54]. Fi-
brinogen levels were determined in citrate plasma according to 
Clauss with a BCS-XP analyzer (Siemens Healthcare Diagnostics). 
Platelets were counted in EDTA whole-blood samples using Sys-
mex XT2000, XE5000, or SE9000 analyzers (Sysmex, Kobe, Japan) 
or Advia (Siemens Healthcare Diagnostics). 
Selection of the Study Population
We excluded from the SHIP-Trend participants (n = 4,420) all 
men and women with missing data on exposure, outcome, or con-
founders (n = 441) for the statistical analyses. From the remaining 
subjects we excluded all of those (overlap exists) with renal disease, 
defined as an estimated glomerular filtration rate < 30 mL/min/ 
1.73 m2, or missing information on renal disease (n = 7), suspected 
hyperparathyroidism, defined as parathyroid hormone levels > 120 
pg/mL (n = 7), intake of parathyroid hormone or vitamin D sup-
plements (ATC H05AA and A11CC, n = 32), and all pregnant 
women. The resulting study population consisted of 3,926 partici-
pants aged between 20 and 84 years. 
Statistical Analyses 
Statistical analyses were performed using SPSS version 23 
(SPSS Inc., Chicago, IL, USA) and SAS 9.4 (SAS Institute Inc., 
Cary, NC, USA). The general characteristics of our study partici-
pants grouped into (1) not depressed and not obese, (2) depressed 
or obese, and (3) depressed and obese individuals are given in 
Table 1. Categorical data are given as proportions; continuous data 
are given as medians (1st to 3rd quartiles). For group comparisons 
Kruskal-Wallis or χ2 tests were used. p < 0.05 was considered sta-
tistically significant. 
Table 1. Characteristics of the study population
Characteristics No depression and no 
obesity (n = 2,539)
Depression or obesity
(n = 1,285)
Depression and obesity 
(n = 102)
p
Sex <0.010
Male 53.0 42.6 24.5
Premenopausal women 24.8 19.7 20.6
Postmenopausal women 22.1 37.7 54.9
Age, years 48.0 (36.0–61.0) 57.0 (46.0–67.0) 54.0 (47.0–61.0) <0.001
Smoking 0.038
Nonsmokers 36.3 36.3 30.4
Former smokers 35.6 39.6 39.2
Current smokers 28.1 24.1 30.4
Physically inactive 51.0 57.2 63.7 <0.001
Antidiabetic drugs 4.6 12.9 14.7 <0.001
Lipid-lowering drugs 10.2 18.5 17.7 <0.001
Antihypertensive drugs 29.2 51.0 53.9 <0.001
Antidepressant drugs 3.5 7.0 22.6 <0.001
Sleep disorders1 85.7
WHR 0.84 (0.80–0.93) 0.92 (0.87–1.01) 0.90 (0.87–1.00) <0.001
PHQ-9 3.0 (1.0–5.0) 3.0 (1.0–7.0) 12.0 (10.0–15.0) <0.001
BDNF, pg/mL 21,363 (17,775–25,331) 21,363 (17,250–25,721) 22,487 (16,003–26,763) 0.772
PLT, GPT/L 222 (191–259) 227 (190–264) 231 (187–280) 0.201
Fibrinogen, g/L 2.90 (2.40–3.40) 3.20 (2.70–3.60) 3.30 (2.70–3.80) <0.001
25(OH)D, ng/mL 23.3 (17.3–29.9) 21.4 (16.4–27.3) 18.7 (14.4–24.9) <0.001
Season 0.415
Winter 51.8 51.8 45.1
Summer 48.3 48.3 54.9
The total number of patients was 3,926. Values are presented as medians (first to third quartiles) or percent. Group differ-
ences were tested with Kruskal-Wallis (continuous data) or χ2 tests (nominal data). BDNF (serum), brain-derived neurotrophic 
factor; PHQ-9, Patient Health Questionnaire; PLT, platelet count; WHR, waist-to-hip ratio; 25(OH)D, 25-hydroxy vitamin D; no 
depression, PHQ-9 score <10; depression, PHQ-9 score ≥10; not obese, WHR <0.85 (females) or <1.00 (males); obese, WHR ≥0.85 
(females) or ≥1.00 (males). 1 Proportion of participants with sleep disorders, including insomnia or hypersomnia or inability to 
fall and stay asleep, for at least 2 weeks among 102 subjects with depression and obesity. 
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We firstly assessed whether BDNF and vitamin D serum levels 
were related by performing a partial correlation analysis adjusting 
for sex, age, platelets, and season. Afterwards, we examined the 
associations of BDNF and vitamin D (continuous exposure vari-
ables) with depression or obesity (dichotomous outcome vari-
ables) in multivariable binary logistic regression models. In these 
models we also examined whether the participants’ vitamin D sta-
tus was a potential effect modifier by testing the interaction of 
BDNF and vitamin D. We additionally used multinomial logistic 
regression to assess whether increasing BDNF or vitamin D serum 
levels (continuous exposure variables) are related to higher odds 
of being not depressed and not obese compared to being de-
pressed and obese (categorized outcome variable). We further as-
sessed the associations between BDNF or vitamin D (continuous 
exposure variables) and depression severity (categorized outcome 
variable) in multinomial logistic regression and used multivari-
able linear regression models to assess the associations between 
BDNF or vitamin D (continuous exposure variables) and the 
WHR (continuous outcome variable). To account for nonlinear-
ity, we added restricted cubic splines with 3 knots to the linear 
regression models. The three knots were prespecified, located at 
the 5th, 50th, and 95th percentiles, resulting in one component of 
the spline function, which was named BDNF’ or vitamin D’, re-
spectively. Whether the overall effect of the exposure was different 
from zero was tested with a Wald χ2 test. We report β-coefficients 
with standard errors SE and p values from the linear regression 
models and OR with 95% CI and p values from the logistic regres-
sion models. To describe the overall model fit we reported F and 
p values as well as the adjusted R2 for the linear regression models 
and χ2 and p values as well as Nagelkerke’s R2 for the binary and 
multinomial logistic regression models. To take confounding into 
account, we calculated 3 sets for each model with different adjust-
ments. Model 1 was unadjusted; model 2 was adjusted for sex, age, 
physical inactivity, and smoking and additionally for WHR in 
models with depression as the outcome; and model 3 was addi-
tionally adjusted for platelets and fibrinogen in models with 
BDNF as exposure or for season in models with vitamin D as ex-
posure. To account for multiple testing, we used the Bonferroni 
correction to assess statistical significance in the regression mod-
els. In total we tested the associations between 2 exposure vari-
ables (BDNF and vitamin D) and 5 outcome variables (depres-
sion, obesity, depression/obesity group, depression severity, and 
WHR), yielding a Bonferroni-corrected statistical significance at 
p < 0.005 (i.e., 0.05/10). 
Results
Table 1 shows the baseline characteristics of the study 
sample stratified into not depressed or not obese (n = 
2,539), depressed or obese (n = 1,285), and depressed and 
obese (n = 102) individuals. Women were overrepresent-
ed in the depressed or obese group and also in the de-
pressed and obese group. Not depressed and not obese 
subjects were younger and less often physically inactive 
and had a lower WHR and higher vitamin D concentra-
tions than subjects in the other 2 groups. Moreover, in-
take of antidiabetic, lipid-lowering, or antihypertensive 
medication was substantially less frequent in subjects 
without depression or obesity than in the other groups. 
Antidepressant drug intake was highest among depressed 
and obese individuals, with more than 22% of subjects in 
Table 2. Associations of BDNF or vitamin D serum levels with depression or obesity
Outcome Model BDNF Vitamin D BDNF × vitamin D 
interaction
OR 
(95% CI)
p χ2 (p) R2 OR 
(95% CI)
p χ2 (p) R2 OR 
(95% CI)
p
Depression 1 0.997
(0.977–1.017)
0.754 0.1
(0.753)
<0.001 0.973
(0.959–0.987)
<0.001 15.5
(<0.001)
0.010 1.002
(1.000–1.004)
0.105
2 0.992
(0.972–1.013)
0.451 46.8
(<0.001)
0.029 0.976
(0.962–0.990)
<0.001 58.1
(<0.001)
0.036 1.002
(1.000–1.005)
0.057
3 0.995
(0.974–1.017)
0.681 50.1
(<0.001)
0.031 0.966
(0.951–0.981)
<0.001 70.0
(<0.001)
0.044 1.002
(1.000–1.005)
0.065
Obesity 1 1.000
(0.989–1.011)
0.954 <0.1
(0.950)
<0.001 0.974
(0.966–0 981)
<0.001 47.9
(<0.001)
0.017 1.000
(0.998–1.001)
0.467
2 0.997
(0.986–1.009)
0.656 353.1
(<0.001)
0.121 0.980
(0.972–0.988)
<0.001 377.1
(<0.001)
0.129 0.999
(0.998–1.000)
0.165
3 0.995
(0.982–1.007)
0.393 411.8
(<0.001)
0.141 0.976
(0 967–0.985)
<0.001 383.3
(<0.001)
0.131 0.999
(0.998–1.000)
0.117
Results from binary logistic regression models (n = 3,926). Depression was defined as a Patient Health Questionnaire score ≥10. Obesity was defined as 
a waist-to-hip ratio ≥0.85 (females) or ≥1.00 (males). In the logistic regression models, an increase of 1,000 pg/mL in BDNF and of 1 ng/mL in vitamin D 
was modeled. Model 1 = unadjusted; model 2 = adjusted for sex, age, physical activity, and smoking and for WHR in depression models; model 3 = model 
2 + platelets and fibrinogen in BDNF models or + season in vitamin D models. The overall model fit is given by the χ2 (p) values as well as Nagelkerke’s R2. 
BDNF, brain-derived neurotrophic factor.
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reporting a respective medication intake. BDNF concen-
trations and platelet counts were similar between the 3 
groups. 
The logistic regression models revealed no association 
between BDNF and depression or obesity, while vitamin 
D was inversely associated with both outcomes in all 
models (Table 2). Thus, increasing vitamin D levels was 
associated with decreased odds of depression or obesity. 
The fully adjusted multinomial logistic regression model 
(Table 3) also revealed no associations with BDNF but as-
sociations with vitamin D. We found that a 1 ng/mL in-
crease in vitamin D levels was related to a 6.1% higher 
odds of being not depressed and not obese versus being 
depressed and obese (p < 0.001). We further observed 
4.3% higher odds of being either depressed or obese ver-
sus being depressed and obese with a 1 ng/mL increase in 
vitamin D levels (p = 0.005). However, this association 
was on the threshold of statistical significance after cor-
rection for multiple testing. The results from the previous 
2 analyses were supported by the observations regarding 
depression severity. There was no association between 
BDNF and depression severity but there was one between 
vitamin D and depression severity (Table 4). In the fully 
adjusted model 3, an increase in vitamin D of 1 ng/ml was 
associated with an OR of 1.076 (95% CI 1.037–1.116, 
p < 0.001) for having a PHQ-9 score < 5 compared to a 
PHQ-9 score ≥15. Overall, the associations of vitamin D 
with depression or depression severity remained signifi-
cant after correction for multiple testing, and only the 
odds for moderate versus moderately severe or severe de-
pression missed the Bonferroni-corrected statistical sig-
nificance threshold.
We found a very weak partial correlation between 
BDNF and vitamin D (partial correlation coefficient 
0.006, p < 0.001) but the interaction of BDNF and vitamin 
D missed statistical significance in the model for depres-
sion (Table 2; model 1: p = 0.105, model 2: p = 0.057, and 
model 3: p = 0.065). Interactions of BDNF and vitamin D 
on obesity were also not statistically significant (Table 2; 
model 1: p = 0.467, model 2: p = 0.165, and model 3: p = 
0.117). 
Finally, we assessed the associations of BDNF and vi-
tamin D with WHR (Table 5; Fig. 1). We found significant 
nonlinear associations of BDNF or vitamin D with WHR. 
Regarding BDNF, the fully adjusted model showed a U-
shaped association with a nadir at 23,000 pg/mL of BDNF. 
Regarding vitamin D, the fully adjusted model demon-
strated a linear decrease in WHR starting at vitamin D 
concentrations of about 25 ng/mL and a constant WHR 
when the vitamin D level was below this threshold. These 
associations were also robust to the correction for mul-
tiple testing.
Table 3. Associations of BDNF or vitamin D serum levels with depression and obesity
Model Outcome BDNF Vitamin D
OR (95% CI) p χ2 (p) R2 OR (95% CI) p χ2 (p) R2
1 No depression and no obesity 0.994 (0.963–1.027) 0.731 1.059 (1.032–1.086) <0.001
Depression or obesity 0.993 (0.961–1.026) 0.653 0.26 <0.001 1.032 (1.005–1.059) 0.018 62.1 0.02
Depression and obesity Reference (–0.8783) Reference (<0.001)
Joint effect 0.878 Joint effect <0.001
2 No depression and no obesity 1.008 (0.975–1.041) 0.656 1.046 (1.016–1.076) 0.002
Depression or obesity 1.003 (0.970–1.037) 0.866 309.4 0.098 1.031 (1.003–1.060) 0.028 2,757.2 0.652
Depression and obesity Reference (<0.001) Reference (<0.001)
Joint effect 0.690 Joint effect 0.004
3 No depression and no obesity 1.004 (0.970–1.040) 0.814 1.061 (1.029–1.095) <0.001
Depression or obesity 0.997 (0.962–1.033) 0.859 368.6 0.116 1.043 (1.013–1.074) 0.005 2,764.3 0.654
Depression and obesity Reference (<0.001) Reference (<0.001)
Joint effect 0.503 Joint effect <0.001
Results from multinomial logistic regression models (n = 3,926). In the multinomial logistic regression models, an increase of 1,000 pg/mL in BDNF and 
of 1 ng/mL in vitamin D was modeled. The joint effect of the exposure was tested with a Wald χ2 test. Model 1 = unadjusted; model 2 = adjusted for sex, age, 
physical activity, and smoking; model 3 = model 2 + platelets and fibrinogen in BDNF models or + season in vitamin D models. The overall model fit is 
given by the χ2 (p) values as well as Nagelkerke’s R2. BDNF, brain-derived neurotrophic factor.
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Table 4. Associations of BDNF or vitamin D serum levels with PHQ-9
Model PHQ-9 
score
BDNF Vitamin D
OR (95% CI) p χ2 (p) R2 OR (95% CI) p χ2 (p) R2
1 <5 1.012 (0.971–1.055) 0.562 1.076 (1.040–1.114) <0.001
5–9 1.026 (0.984–1.070) 0.228 1.063 (1.026–1.100) <0.001
10–14 1.017 (0.971–1.065) 0.479 5.8 0.002 1.054 (1.015–1.093) 0.006 33.9 0.011
≥15 Reference (0.120) Reference (<0.001)
Joint effect 0.120 Joint effect <0.001
2 <5 1.020 (0.979–1.064) 0.346 1.068 (1.032–1.106) <0.001
5–9 1.028 (0.985–1.073) 0.199 1.056 (1.020–1.093) 0.002
10–14 1.019 (0.972–1.068) 0.431 140.8 0.043 1.048 (1.010–1.087) 0.014 164.6 0.050
≥15 Reference (<0.001) Reference (<0.001)
Joint effect 0.423 Joint effect <0.001
3 <5 1.016 (0.972–1.062) 0.488 1.076 (1.037–1.116) <0.001
5–9 1.028 (0.983–1.075) 0.232 1.059 (1.020–1.099) 0.003
10–14 1.019 (0.970–1.071) 0.451 152.3 0.047 1.042 (1.001–1.084) 0.045 185.0 0.056
≥15 Reference (<0.001) Reference (<0.001)
Joint effect 0.271 Joint effect <0.001
Results from multinomial logistic regression models (n = 3,926). In the multinomial logistic regression models, an increase of 1,000 
pg/mL in BDNF and of 1 ng/mL in vitamin D was modeled. The joint effect of the exposure was tested with a Wald χ2 test. Model 1 = 
unadjusted; model 2 = adjusted for sex, age, physical activity, and smoking, and for WHR in depression models; model 3 = model 2 + 
platelets and fibrinogen in BDNF models or + season in vitamin D models. The overall model fit is given by the χ2 (p) values as well as 
Nagelkerke’s R2. BDNF, brain-derived neurotrophic factor; PHQ-9, Patient Health Questionnaire.
Table 5. Associations of BDNF or vitamin D serum levels with WHR
Model BDNF Vitamin D
exposure β coefficient SE p F value
(p)
R2 exposure β coefficient SE p F value
(p)
R2
1 BDNF –4.55×10–3 5.65×10–4 <0.001 42.6 0.021 Vitamin D 1.57×10–3 4.13×10–4 <0.001 31.1 0.015
BDNF’ 9.60×10–6 1.77×10–6 <0.001 (<0.001) Vitamin D’ –3.84×10–6 6.27×10–7 <0.001 (<0.001)
Overall <0.001 Overall <0.001
2 BDNF –1.74×10–3 3.86×10–4 <0.001 681.3 0.548 Vitamin D 2.73×10–4 2.81×10–4 0.332 685.1 0.550
BDNF’ 5.09×10–6 1.21×10–6 <0.001 (<0.001) Vitamin D’ –1.30×10–6 4.26×10–7 0.002 (<0.001)
Overall <0.001 Overall <0.001
3 BDNF –1.75×10–3 3.89×10–4 <0.001 546.6 0.556 Vitamin D 1.01×10–4 2.89×10–4 0.728 601.2 0.550
BDNF’ 4.71×10–6 1.20×10–6 <0.001 (<0.001) Vitamin D’ –1.20×10–6 4.28×10–7 0.005 (<0.001)
Overall <0.001 Overall <0.001
Results from linear regression models with restricted cubic splines with 3 knots (n = 3,926). In the regression models, an increase of 1,000 pg/mL in 
BDNF and of 1 ng/mL in vitamin D was modeled. BDNF’ and vitamin D’ denote the spline components. The overall effect of the exposure was tested with 
a Wald χ2 test. Model 1 = unadjusted; model 2 = adjusted for sex, age, physical activity, and smoking; model 3 = model 2 + platelets and fibrinogen in BDNF 
models or + season in vitamin D models. The overall model fit is given by the F and p values as well as the adjusted R2. BDNF, brain-derived neurotrophic 
factor; WHR, waist-to-hip ratio.
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Discussion
In the present cross-sectional study we investigated 
the associations of BDNF and vitamin D with depres-
sion, measured with the PHQ-9 [50], and obesity, mea-
sured with the WHR [52], in 3,926 adult individuals 
from the general population. While BDNF was not as-
sociated with depression, we revealed a U-shaped asso-
ciation of BDNF with WHR. Moreover, inverse associa-
tions of vitamin D with depression and obesity were 
found. 
Our hypothesis about an inverse association of BDNF 
and depression was not confirmed. Indeed, there was no 
statistically significant association between BDNF and 
depression or depression severity. A meta-analysis from 
2014 [7] reported an inverse association of BDNF and 
depression but pointed out that evidence for this asso-
ciation was less than initially thought. Besides, these au-
thors questioned the influence of BDNF released from 
peripheral tissues on the investigated association of 
BDNF and depression [7]. Similarly, Chacón-Fernández 
et al. [13] and Serra-Millàs [55] investigated the influ-
ence of BDNF released from platelets and megakaryo-
cytes and proposed that alterations in serum BDNF lev-
els result from changes in platelets [13, 55]. However, 
adjusting for platelet counts did not significantly change 
the results of this study. Another aspect of this result 
might be that pro-BDNF, the precursor of mature BDNF, 
is biologically active, too [56, 57]. Pro-BDNF plays an 
important role in multiple physiological processes and 
partially shows effects different from those of mature 
BDNF [8]. Hence, we recommend distinguishing be-
tween pro-BDNF and BDNF for future studies. Another 
aspect for the lack of an association between BDNF and 
depression may be found in the small proportion (1.6%) 
of moderately severe or severely depressed individuals. 
We cannot exclude that associations between BDNF and 
PHQ-9 are present in severely ill patients, who are found 
in clinical samples. 
Regarding BDNF, we did not detect an inverse asso-
ciation with WHR, as hypothesized, but we did find a 
U-shaped association. Previously, an inverse association 
between BMI or body fat mass and BDNF was observed 
in children after adjusting for platelets, age, and pubertal 
status [20]. Other studies suggested a positive associa-
tion between BDNF and BMI: Monteleone et al. [21]  
investigated this association in women with anorexia 
nervosa and obesity. Likewise, Nakazato et al. [23] con-
sidered 30 young women (age range: 14–34 years) with 
anorexia nervosa and bulimia nervosa, 10 of whom took 
antipsychotic drugs [23]. All of these studies [20, 21, 23, 
58] did not adjust for platelets, had a small sample size, 
BDNF, pg/mL
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0.85
1.05
0.75
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W
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Fig. 1. Associations of brain derived neurotrophic factor (BDNF) 
or vitamin D with waist-to-hip ratio (WHR). Regression lines from 
3 linear regression models with restricted cubic splines (3 knots). 
The grey solid lines represent the results from model 1 (unadjust-
ed), the grey dashed lines represent the results from model 2 (ad-
justed for sex, age, physical activity, and smoking status), and the 
black solid lines represent the results from model 3 (model 2 + 
platelets and fibrinogen in BDNF models or + season in vitamin D 
models). The grey shaded areas indicated the central 95% range of 
the BDNF or vitamin D distribution, respectively. 25(OH)D, 
25-hydroxy vitamin D.
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and investigated diseased individuals only. Therefore, 
these results cannot be transferred to the general popula-
tion or be compared to our results. Huang et al. [58] 
found no association between BDNF and obesity but 
they did find one between BDNF and interleukin 6 in 31 
obese and non-obese individuals [58]. The authors men-
tion that increasing BDNF levels may have a neuropro-
tective effect in inflammation caused by obesity [58]. 
This might be one explanation for our results of high 
BDNF levels in subjects with a high WHR. A study in-
cluding 144 individuals found no correlation between 
BDNF and interleukin 6, and the authors query the find-
ings of Huang et al. [58, 59]. However, the mechanisms 
of a potential association of BDNF with obesity are not 
sufficiently determined to date. In rodents, BDNF was 
found to control appetite by melanocortin signaling, 
thereby influencing obesity [60]. Additionally an asso-
ciation between BDNF gene variants and obesity was 
postulated in another study [61]. An fMRI pilot study in 
48 healthy individuals found a positive correlation of se-
rum BDNF with connectivity in the (pre-)motor hub. 
Especially in older adults BDNF levels were associated 
with physical activity and learning capacities [62]. How-
ever, existing results regarding the association of BDNF 
and physical activity are conflicting, as studies show that 
endurance training is not related to BDNF levels in el-
derly persons [63]. Future studies are needed to confirm 
our results regarding the association of BDNF with obe-
sity and to reveal causation.
Our study revealed a very weak correlation between 
BDNF and vitamin D. Furthermore we did not find an 
interaction of BDNF and vitamin D on depression. This 
is in line with previous studies that found associations of 
BDNF and vitamin D or vitamin D supplementation 
with depression but reported no interactions between 
the measures [64, 65]. In summary, our hypothesis of an 
interaction between vitamin D and BDNF with obesity 
was not confirmed.
We revealed an inverse association of vitamin D with 
depressive symptoms. Thus, our results are consistent 
with our hypothesis and confirm previous findings [31–
33, 66]. Vitamin D is known to be involved in brain func-
tions and passes the blood-brain barrier, and vitamin D 
receptors are copious distributed in the brain [67]. We 
saw that a 1 ng/mL increase in vitamin D was related to 
6.1% higher odds of being neither depressed nor obese 
versus being depressed and obese (p < 0.001). This might 
not have clinical relevance at first sight, but Jorde et al. 
[68] showed in a randomized double blind clinical trial 
effects in supplementation of vitamin D compared to 
placebo in obese and overweight depressed patients over 
a year in decreasing depression scores. Several mecha-
nisms are known to cause this inverse association. First-
ly, vitamin D is involved in neuroplasticity [35, 36]. Sec-
ondly, depressive disorders are linked to factors that di-
rectly influence vitamin D. Persons suffering from 
depressive disorders often have reduced sun exposure, 
less engagement in physical activity, and a poorer diet 
[66]. Thirdly, depressive individuals show a deregulated 
function of the hypothalamic-pituitary-adrenal axis and 
sympathoadrenal hyperactivity, combined with elevated 
levels of inflammatory mediators [69]. Vitamin D has 
been found to play a role in chronic inflammation [70] 
and to reduce inflammatory mediators [66]. However, 
further studies are required to ensure understanding 
these mechanisms and to determine causation.
In accordance to our hypothesis we found an inverse 
association of vitamin D and WHR for vitamin D 
concentrations starting at about 25 ng/mL. Below this 
threshold the WHR remained constant. These results 
confirmed previous findings [41–43]. Most obese indi-
viduals in our study were postmenopausal women. Dur-
ing menopause a decline in estrogens affects numerous 
metabolic processes such as changes in body composi-
tion [71]. LeBlanc et al. [72] suggested that low vitamin 
D may be a predisposition for fat accumulation as high-
er vitamin D levels have been found to be associated with 
a lower gain in weight.
The main strength of our study is its population-
based approach, including the large number of subjects. 
Data were acquired in a standardized setting. Further, in 
contrast to previous studies, we were able to adjust for a 
broad range of confounding factors. On the other hand, 
its cross-sectional design was a limitation since it does 
not allow determination of causation in the investigated 
associations. Additionally, the proportion of subjects 
who were moderately severely or severely depressed 
(PHQ-9 score ≥15) was very small (i.e., 1.6%), and thus, 
we cannot exclude that associations between BDNF and 
PHQ-9 are present in severely ill patients. Aside from 
this, there is no information on other psychiatric disor-
ders, e.g., anxiety disorders, obsessive compulsive disor-
der or psychotic symptoms, and only little information 
on sleep disorders, which often accompany depressive 
symptoms. Moreover, all analyses are based on single-
occasion measurements, which were taken throughout 
the year. However season of blood sampling was taken 
into account in the statistical analyses.
To the best of our knowledge this is one of the first 
studies to investigate associations of BDNF and vitamin 
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D with depression and obesity and their interaction in a 
large population-based sample. The observed U-shaped 
association between BDNF and WHR as well as the mar-
ginally significant interaction of BDNF and vitamin D 
on depression may indicate a potential combined effect 
of these 2 players in brain development on depression. 
At the population level, our results support the relevant 
roles of vitamin D and BDNF in health-related out-
comes. Further research focusing on vitamin D and 
BDNF is necessary to substantiate these results.
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